AU2009295168B2 - The salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide - Google Patents
The salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide Download PDFInfo
- Publication number
- AU2009295168B2 AU2009295168B2 AU2009295168A AU2009295168A AU2009295168B2 AU 2009295168 B2 AU2009295168 B2 AU 2009295168B2 AU 2009295168 A AU2009295168 A AU 2009295168A AU 2009295168 A AU2009295168 A AU 2009295168A AU 2009295168 B2 AU2009295168 B2 AU 2009295168B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- mesylate
- salt
- ptk787
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 29
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical class C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 title claims abstract description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000003814 drug Substances 0.000 claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 9
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 17
- 229940126062 Compound A Drugs 0.000 description 111
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 111
- 241000700159 Rattus Species 0.000 description 58
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 37
- 229950000578 vatalanib Drugs 0.000 description 37
- 238000002474 experimental method Methods 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 230000005764 inhibitory process Effects 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 238000012453 sprague-dawley rat model Methods 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 206010009944 Colon cancer Diseases 0.000 description 15
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 15
- 208000029742 colonic neoplasm Diseases 0.000 description 15
- 239000013078 crystal Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 229910019142 PO4 Inorganic materials 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000010171 animal model Methods 0.000 description 12
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 12
- 238000011580 nude mouse model Methods 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 12
- 239000010452 phosphate Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 12
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 10
- 108091008605 VEGF receptors Proteins 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 9
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 7
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 102000001332 SRC Human genes 0.000 description 6
- 108060006706 SRC Proteins 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 4
- 238000001949 anaesthesia Methods 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 229940120638 avastin Drugs 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 101150048336 Flt1 gene Proteins 0.000 description 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- -1 PDGFR-p Proteins 0.000 description 3
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229960000241 vandetanib Drugs 0.000 description 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 3
- BMSZNJAHQMIOMH-ODZAUARKSA-N (z)-but-2-enedioic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.OC(=O)\C=C/C(O)=O BMSZNJAHQMIOMH-ODZAUARKSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BYMMIQCVDHHYGG-UHFFFAOYSA-N Cl.OP(O)(O)=O Chemical compound Cl.OP(O)(O)=O BYMMIQCVDHHYGG-UHFFFAOYSA-N 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- AYLAUQNOWYVDAI-GRHBHMESSA-N (Z)-but-2-enedioic acid methanesulfonic acid phosphoric acid hydrochloride Chemical compound Cl.CS(O)(=O)=O.OP(O)(O)=O.OC(=O)\C=C/C(O)=O AYLAUQNOWYVDAI-GRHBHMESSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- HTPCDVLWYUXWQR-UHFFFAOYSA-N 2-aminopyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1N HTPCDVLWYUXWQR-UHFFFAOYSA-N 0.000 description 1
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
- 240000005369 Alstonia scholaris Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- NXZGHWRGVZZWBX-UHFFFAOYSA-N C(CCC(=O)O)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(C=C/C(=O)O)(=O)O.P(=O)(O)(O)O.S(=O)(=O)(O)O.S(C)(=O)(=O)O Chemical compound C(CCC(=O)O)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(C=C/C(=O)O)(=O)O.P(=O)(O)(O)O.S(=O)(=O)(O)O.S(C)(=O)(=O)O NXZGHWRGVZZWBX-UHFFFAOYSA-N 0.000 description 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 101100041249 Chlorobaculum tepidum (strain ATCC 49652 / DSM 12025 / NBRC 103806 / TLS) rub1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100083342 Mus musculus Picalm gene Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101100018718 Rattus norvegicus Il1rl1 gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241001319955 Unda Species 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940043239 cytotoxic antineoplastic drug Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101496511A CN101676267B (zh) | 2008-09-16 | 2008-09-16 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
| CN200810149651.1 | 2008-09-16 | ||
| PCT/CN2009/072239 WO2010031266A1 (zh) | 2008-09-16 | 2009-06-11 | N-[4-(1-氰基环戊基)苯基]-2-（4-吡啶甲基）氨基-3-吡啶甲酰胺的盐 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009295168A1 AU2009295168A1 (en) | 2010-03-25 |
| AU2009295168B2 true AU2009295168B2 (en) | 2014-02-13 |
Family
ID=42029001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009295168A Active AU2009295168B2 (en) | 2008-09-16 | 2009-06-11 | The salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide |
Country Status (13)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104072413A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用 |
| CN104086484B (zh) * | 2014-07-08 | 2016-05-25 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用 |
| CN104086483A (zh) * | 2014-07-08 | 2014-10-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐f晶型及其制备方法和应用 |
| CN104072411A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐c晶型及其制备方法和应用 |
| CN104072412A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 |
| CN104072410B (zh) * | 2014-07-08 | 2017-02-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐d晶型及其制备方法和应用 |
| CN105622499A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
| CN105622498A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
| CN105541708A (zh) * | 2014-10-28 | 2016-05-04 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
| US10472482B2 (en) | 2015-04-15 | 2019-11-12 | Dow Global Technologies Llc | Thermally insulating foam with vertically elongated cells |
| CN105801476A (zh) * | 2016-04-13 | 2016-07-27 | 上海宣创生物科技有限公司 | 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用 |
| CN106243031B (zh) * | 2016-07-26 | 2017-09-08 | 江苏恒瑞医药股份有限公司 | 一种阿帕替尼的制备方法 |
| TWI764943B (zh) | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
| WO2018099423A1 (zh) | 2016-12-01 | 2018-06-07 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途 |
| CN108250138A (zh) * | 2016-12-28 | 2018-07-06 | 上海宣创生物科技有限公司 | 阿帕替尼a晶型及其制备方法和应用 |
| CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
| CN109381436A (zh) * | 2017-08-14 | 2019-02-26 | 江苏恒瑞医药股份有限公司 | 阿帕替尼药物组合物及其制备方法 |
| CN109394685B (zh) * | 2017-08-15 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂的药物组合物及其制备方法 |
| WO2019034048A1 (zh) * | 2017-08-15 | 2019-02-21 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂晶型及其制备方法 |
| WO2019094832A1 (en) * | 2017-11-10 | 2019-05-16 | Lsk Biopharma | A combination therapy with apatinib for the treatment of cancer |
| TW201924720A (zh) | 2017-12-06 | 2019-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｐａｒｐ抑制劑用於治療化療耐藥的卵巢癌或乳腺癌的用途 |
| CN109942487A (zh) * | 2017-12-21 | 2019-06-28 | 江苏恒瑞医药股份有限公司 | 一种吡啶类化合物及其制备方法、用途 |
| MX2020006368A (es) | 2017-12-29 | 2020-08-17 | Jiangsu Hengrui Medicine Co | Uso de tratamiento combinado de anticuerpo pd-1 y apatinib para tratar cancer de mama triple negativo. |
| EP3847164A1 (en) * | 2018-09-05 | 2021-07-14 | Assia Chemical Industries Ltd | New crystalline polymorphs of rivoceranib and rivoceranib mesylate |
| CN115279405A (zh) * | 2020-04-10 | 2022-11-01 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040259916A1 (en) * | 2003-06-16 | 2004-12-23 | Chen Guoqing P. | Six membered amino-amide derivatives an angiogenisis inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| CA2493026C (en) * | 2002-07-31 | 2011-05-24 | Schering Aktiengesellschaft | Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines |
| CN1281590C (zh) * | 2002-11-27 | 2006-10-25 | 南京凯衡科贸有限公司 | 具有抑制血管生成活性的六员氨基酰胺类衍生物 |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
-
2008
- 2008-09-16 CN CN2008101496511A patent/CN101676267B/zh active Active
-
2009
- 2009-06-11 US US13/063,850 patent/US8362256B2/en active Active
- 2009-06-11 BR BRPI0919018A patent/BRPI0919018A2/pt not_active Application Discontinuation
- 2009-06-11 AU AU2009295168A patent/AU2009295168B2/en active Active
- 2009-06-11 WO PCT/CN2009/072239 patent/WO2010031266A1/zh active Application Filing
- 2009-06-11 RU RU2011113229/04A patent/RU2499796C2/ru active
- 2009-06-11 JP JP2011526364A patent/JP5649132B2/ja active Active
- 2009-06-11 KR KR1020117008504A patent/KR101674227B1/ko active IP Right Grant
- 2009-06-11 EP EP09813987.6A patent/EP2327697B1/en active Active
- 2009-06-11 CA CA2736664A patent/CA2736664C/en active Active
- 2009-06-11 MX MX2011002816A patent/MX2011002816A/es active IP Right Grant
-
2010
- 2010-08-18 HK HK10107871.7A patent/HK1141514A1/xx unknown
-
2011
- 2011-03-11 ZA ZA2011/01891A patent/ZA201101891B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040259916A1 (en) * | 2003-06-16 | 2004-12-23 | Chen Guoqing P. | Six membered amino-amide derivatives an angiogenisis inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2327697B1 (en) | 2014-03-12 |
| CA2736664C (en) | 2016-05-24 |
| RU2499796C2 (ru) | 2013-11-27 |
| AU2009295168A1 (en) | 2010-03-25 |
| JP5649132B2 (ja) | 2015-01-07 |
| CA2736664A1 (en) | 2010-03-25 |
| JP2012502885A (ja) | 2012-02-02 |
| EP2327697A1 (en) | 2011-06-01 |
| CN101676267A (zh) | 2010-03-24 |
| BRPI0919018A2 (pt) | 2015-12-08 |
| KR101674227B1 (ko) | 2016-11-08 |
| HK1141514A1 (US20080131398A1-20080605-C00009.png) | 2010-11-12 |
| US20110184023A1 (en) | 2011-07-28 |
| WO2010031266A1 (zh) | 2010-03-25 |
| MX2011002816A (es) | 2011-04-05 |
| KR20110059877A (ko) | 2011-06-07 |
| US8362256B2 (en) | 2013-01-29 |
| RU2011113229A (ru) | 2012-10-27 |
| CN101676267B (zh) | 2012-12-26 |
| ZA201101891B (en) | 2012-05-30 |
| EP2327697A4 (en) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009295168B2 (en) | The salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide | |
| AU2021204278B2 (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | |
| CN110582483B (zh) | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 | |
| TWI324066B (en) | A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor | |
| NO344272B1 (no) | Termodynamisk stabil form av BAY 43-9006 tosylat | |
| CN105452227B (zh) | {[1-氰基-5-(4-氯苯氧基)-4-羟基-异喹啉-3-羰基]-氨基}-乙酸的晶形 | |
| EP2796451B1 (en) | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof | |
| CN104592105A (zh) | 瑞戈非尼及其制法 | |
| WO2014040242A1 (zh) | 3-氯-及3-甲氧基-n-甲基-2-吡啶酰胺化合物及其作为抗癌药物的应用 | |
| KR20100029097A (ko) | 안트라닐아미드 피리딘우레아와 벤즈아미드 유도체의 상승작용적 조합물 | |
| WO2013107225A1 (zh) | N-（（4-氯-3-三氟甲基）苯基）-n'-（2-氟-4-（（2-羟甲基氨基甲酰基)-4-吡啶基氧）苯基）脲及其作为抗癌药物的应用 | |
| CN109476634B (zh) | 喹唑啉衍生物的盐的晶体 | |
| TW200536529A (en) | Dosage forms and methods of treatment using VEGFR inhibitors | |
| CN110386901B (zh) | 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用 | |
| TWI462738B (zh) | Ｎ－〔４－（１－氰基環戊基）苯基〕－２－（４－吡啶甲基）胺基－３－吡啶甲醯胺的鹽 | |
| CN100427483C (zh) | 邻氨基苯甲酰胺衍生物和其药学用途 | |
| CN114751858B (zh) | 含有喹啉基的氨甲环酸衍生物及其制备与应用 | |
| CN108299397B (zh) | 一种用于降血压的活性药物及其制备方法 | |
| WO2024051702A1 (zh) | 用作cdk4激酶抑制剂的化合物及其应用 | |
| CN103570616B (zh) | N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 | |
| TWI515186B (zh) | 治療腫瘤疾病的醫藥組成物 | |
| NZ723714B2 (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CB | Opposition filed |
Opponent name: LSK BIOPHARMA |
|
| CC | Opposition dismissed |
Opponent name: LSK BIOPHARMA |
|
| FGA | Letters patent sealed or granted (standard patent) |